Canopy Growth Stock
Canopy Growth Corporation
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- Luc Mongeau
- Employees
- 1,128
- Market cap
- $449 M
- IPO
- 17/08/2010
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The…
Canopy Growth stock: price history
1D
-3.8%
1W
-15.3%
1M
-21.9%
6M
-36.3%
YTD
-35.9%
1Y
-47.4%
2Y
-82.9%
5Y
-99.4%
10Y
-98.5%
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~18% weaker price swings than usual
Ask the agents about Canopy Growth
Analyst assessment of Canopy Growth
0
STRONG BUY
8
BUY
7
HOLD
7
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 10/11/2025
Canopy Growth stock metrics
P/E
-1.5
P/B
0.61
EV/EBITDA
-11.59
RETURN ON EQUITY
-2.1%
NET MARGIN
-18.0%
DEBT/EQUITY
0.4
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.6%
FLOAT SHARES
420,663,065
AVG. DAILY VOLUME (30D)
628,199
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Canopy Growth stock
What does Canopy Growth do?
Canopy Growth Corporation is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Luc Mongeau, the company employs around 1,128 people.
The IPO was on 17/08/2010; the stock trades on TSX under the ticker WEED.TO.
What do analysts say about Canopy Growth stock?
22 analysts rate the stock, the consensus is Buy (as of 10/11/2025).
This is an external assessment, not a statement by Market Jury.
When does Canopy Growth report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly -18% stronger than usual.
Does Canopy Growth pay a dividend?
No, Canopy Growth currently does not pay a dividend.
Which stocks are comparable to Canopy Growth?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Canopy Growth stock analyzed?
Clicking "Analyze stock" lets five strategies assess Canopy Growth against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.